Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1385-1393.

Published: 9th April 2019

Authors: Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M et al.

Conclusion

The late results of this trial that included 934 women corroborated the 5-year findings. After 10 years, disease-free survival was no better after axillary dissection (74.9 per cent) than after no dissection (76.8 per cent).

Pubmed Link

Your comments

0 Comments